DX . DOI . ORG {}

Analyzed Page
Matching Content Categories
CMS
Monthly Traffic Estimate
How Does Dx.doi.org Make Money
Keywords
Topics
Schema
Social Networks
External Links
Analytics And Tracking
Libraries
CDN Services

We began analyzing https://www.nature.com/articles/d44148-025-00194-2, but it redirected us to https://www.nature.com/articles/d44148-025-00194-2. The analysis below is for the second page.

Title[redir]:
First all-oral treatment for deadly strain of sleeping sickness now available in Africa
Description:
A 10-day course of a once-daily tablet has been approved to replace a complex hospital-based regimen with at least a 5% fatality rate in the treatment of the severe strain of human African trypanosomiasis. A 10-day course of a once-daily tablet has been approved to replace a complex hospital-based regimen with at least a 5% fatality rate in the treatment of the severe strain of human African trypanosomiasis.

Matching Content Categories {📚}

Science
Careers
Education

Content Management System {📝}

What CMS is dx.doi.org built with?

Custom-built

No common CMS systems were detected on Dx.doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of dx.doi.org audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,868 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Dx.doi.org Make Money? {💸}

We find it hard to spot revenue streams.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Dx.doi.org could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

nature, university, treatment, africa, disease, research, privacy, cookies, sleeping, fexinidazole, content, sickness, osaka, data, sign, strain, african, malawi, essential, advertising, policy, information, news, alloral, deadly, email, rhodesiense, outbreaks, biology, faculty, immunology, japan, california, merced, westlake, china, optional, analysis, media, personal, including, parties, journals, article, fatality, rate, human, trypanosomiasis, francis, district,

Topics {✒️}

scientific research personnel nature portfolio nature africa profit research-oriented university privacy policy nature briefing advertising 1038/d44148-025-00194-2 reprints full access recommend fexinidazole nature social media development complex hospital-based regimen personal data data protection china explore content tenured faculty position privacy journals search log jena university hospital science news southern africa nat africa including recent outbreaks european economic area neglected diseases initiative world health organization symptoms progress quickly arsenic-based drug intravenous injections administered accepting optional cookies nkhotakota district hospital content human african trypanosomiasis african countries supports clinical project leader essential medicines list manage preferences pharmaceutical company sanofi merced invites applications debilitating sleeping sickness future rhodesiense outbreaks parasitic disease transmitted africa email address rhodesiense sleeping sickness tenure-track optional cookies

Schema {🗺️}

WebPage:
      mainEntity:
         headline:First all-oral treatment for deadly strain of sleeping sickness now available in Africa
         description:A 10-day course of a once-daily tablet has been approved to replace a complex hospital-based regimen with at least a 5% fatality rate in the treatment of the severe strain of human African trypanosomiasis. A 10-day course of a once-daily tablet has been approved to replace a complex hospital-based regimen with at least a 5% fatality rate in the treatment of the severe strain of human African trypanosomiasis.
         datePublished:2025-06-25T00:00:00Z
         dateModified:2025-06-25T00:00:00Z
         sameAs:https://doi.org/10.1038/d44148-025-00194-2
         keywords:
            Life Sciences
            general
         image:
            https://images.nature.com/lw1200/magazine-assets/d44148-025-00194-2/d44148-025-00194-2_51144042.jpg
            https://images.nature.com/lw1200/magazine-assets/d44148-025-00194-2/d44148-025-00194-2_51144040.jpg
         isPartOf:
            name:Nature Africa
            issn:
               2730-9878
            type:
               Periodical
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Gilbert Nakweya
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:First all-oral treatment for deadly strain of sleeping sickness now available in Africa
      description:A 10-day course of a once-daily tablet has been approved to replace a complex hospital-based regimen with at least a 5% fatality rate in the treatment of the severe strain of human African trypanosomiasis. A 10-day course of a once-daily tablet has been approved to replace a complex hospital-based regimen with at least a 5% fatality rate in the treatment of the severe strain of human African trypanosomiasis.
      datePublished:2025-06-25T00:00:00Z
      dateModified:2025-06-25T00:00:00Z
      sameAs:https://doi.org/10.1038/d44148-025-00194-2
      keywords:
         Life Sciences
         general
      image:
         https://images.nature.com/lw1200/magazine-assets/d44148-025-00194-2/d44148-025-00194-2_51144042.jpg
         https://images.nature.com/lw1200/magazine-assets/d44148-025-00194-2/d44148-025-00194-2_51144040.jpg
      isPartOf:
         name:Nature Africa
         issn:
            2730-9878
         type:
            Periodical
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Gilbert Nakweya
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical"]:
      name:Nature Africa
      issn:
         2730-9878
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Gilbert Nakweya
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(4)

External Links {🔗}(75)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Prism.js

CDN Services {📦}

Crossref

3.65s.